The effect of tocilizumab on preventing relapses in adult-onset still's disease

A retrospective, single-center study

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset Still's disease (AOSD). Methods. This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). Conclusions.TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.

Original languageEnglish
Pages (from-to)401-404
Number of pages4
JournalModern Rheumatology
Volume25
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Adult-Onset Still's Disease
Recurrence
Interleukin-6 Receptors
tocilizumab
Therapeutics
Age of Onset
C-Reactive Protein
Retrospective Studies
Monoclonal Antibodies

Keywords

  • Adult-onset Still's disease
  • Glucocorticoids
  • Relapse
  • Tocilizumab

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{f21237e3ba594097a31f4ba3f35d1637,
title = "The effect of tocilizumab on preventing relapses in adult-onset still's disease: A retrospective, single-center study",
abstract = "Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset Still's disease (AOSD). Methods. This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100{\%} and 67{\%} at 12 months, respectively; p = 0.03). Conclusions.TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.",
keywords = "Adult-onset Still's disease, Glucocorticoids, Relapse, Tocilizumab",
author = "Naoshi Nishina and Yuko Kaneko and Hideto Kameda and Tsutomu Takeuchi",
year = "2015",
doi = "10.3109/14397595.2014.973659",
language = "English",
volume = "25",
pages = "401--404",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - The effect of tocilizumab on preventing relapses in adult-onset still's disease

T2 - A retrospective, single-center study

AU - Nishina, Naoshi

AU - Kaneko, Yuko

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

PY - 2015

Y1 - 2015

N2 - Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset Still's disease (AOSD). Methods. This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). Conclusions.TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.

AB - Objectives. To investigate the clinical effectiveness of tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor, in preventing relapse in patients with adult-onset Still's disease (AOSD). Methods. This retrospective study included clinical data from 40 patients who underwent regular follow-up at our institution in June 2013. Among these patients, 10 received TCZ. The relapse-free rate was analyzed by the Kaplan-Meier method. Results. The age at disease onset (median, interquartile range [IQR]) was 39 (29-52) years. The duration of disease in June 2013 (median, IQR) was 86 (41-193) months. A total of 87 relapses were documented in 27 patients. Ten patients with refractory or relapsing disease received 8 mg/kg of TCZ every 2-4 weeks. After 6 months of TCZ treatment, the median levels of C-reactive protein significantly decreased from 6.3 to 0.01 mg/dl (p < 0.01). Among these 10 patients, 11 relapses were observed before TCZ treatment, and none were observed after the treatment. The relapse-free rate of the 10 patients after starting TCZ was significantly higher than that of all 40 patients after the initial treatments (100% and 67% at 12 months, respectively; p = 0.03). Conclusions.TCZ effectively prevented relapses of AOSD, and it resolved the disease activity.

KW - Adult-onset Still's disease

KW - Glucocorticoids

KW - Relapse

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84929459963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929459963&partnerID=8YFLogxK

U2 - 10.3109/14397595.2014.973659

DO - 10.3109/14397595.2014.973659

M3 - Article

VL - 25

SP - 401

EP - 404

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 3

ER -